Abstract: Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3? heterodimerization or CDC25A binding to 14-3-3?. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH2 (SEQ ID NO: 1), a second targeting peptide comprising a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO32?)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH2 (SEQ ID NO: 2), and a third targeting peptide comprising a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO32?)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH2 (SEQ ID NO: 3).

Abstract: Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3? heterodimerization or CDC25A binding to 14-3-3?. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Ac-Gln-Arg-Gln-Asn-Ser-(PO32?)-Ala-Pro-Ala-Arg-NH2 (SEQ ID NO: 4) and a second targeting peptide comprising a structure of Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO32?)-Trp-Ala-Gly-NH2 (SEQ ID NO: 5), and a third targeting peptide comprising a modification of or a substituted derivative of the peptide of SEQ ID NO: 4 or SEQ ID NO: 5.

Abstract: Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3? heterodimerization or CDC25A binding to 14-3-3?. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH2 (SEQ ID NO: 1), a second targeting peptide comprising a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO32?)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH2 (SEQ ID NO: 2), and a third targeting peptide comprising a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO32?)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH2 (SEQ ID NO: 3).

Abstract: Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3? heterodimerization or CDC25A binding to 14-3-3?. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Ac-Gln-Arg-Gln-Asn-Ser-(PO32?)-Ala-Pro-Ala-Arg-NH2 (SEQ ID NO: 4) and a second targeting peptide comprising a structure of Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO32?)-Trp-Ala-Gly-NH2 (SEQ ID NO: 5), and a third targeting peptide comprising a modification of or a substituted derivative of the peptide of SEQ ID NO: 4 or SEQ ID NO: 5.

Abstract: Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3? heterodimerization or CDC25A binding to 14-3-3?. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH2 (SEQ ID NO: 1), a second targeting peptide comprising a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO32?)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH2 (SEQ ID NO: 2), and a third targeting peptide comprising a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO32?)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH2 (SEQ ID NO: 3).

Abstract: A tri-gum blend of (a) xanthan gum, (b) gellan gum and (c) pectin gum is used to provide mouthfeel and stability to beverages, preferably smoothie beverages. Xanthan gum is present in an amount ranging from about 0.002% to about 0.5%, preferably from about 0.025% to about 0.055%, more preferably about 0.04%, gellan gum is present in an amount ranging from about 0.002% to about 0.5%, preferably from about 0.008% to about 0.023%, more preferably about 0.015%, and pectin gum is present in an amount ranging from about 0.05% to about 2.0%, preferably from about 0.10% to about 0.30%, more preferably about 0.2%, all by weight of a stable beverage.

Abstract: The present invention provides a method for suppression of ultra violet-induced skin pathologies and skin abnormalities, such as abnormal proliferation and mutagenesis, and for inducing apoptosis in cells having Erbb2 or HER2 receptors. The method involves administration of Erbb2/HER2 inhibitors, either before or after exposure to UV.

Abstract: A method of patching a hole in a wall includes the steps of placing a support on a reverse side of the wall. The support is free floating. Next, a repair compound is applied over the support.

Abstract: A tri-gum blend of (a) xanthan gum, (b) gellan gum and (c) pectin gum is used to provide mouthfeel and stability to beverages, preferably smoothie beverages. Xanthan gum is present in an amount ranging from about 0.002% to about 0.5%, preferably from about 0.025% to about 0.055%, more preferably about 0.04%, gellan gum is present in an amount ranging from about 0.002% to about 0.5%, preferably from about 0.008% to about 0.023%, more preferably about 0.015%, and pectin gum is present in an amount ranging from about 0.05% to about 2.0%, preferably from about 0.10% to about 0.30%, more preferably about 0.2%, all by weight of a stable beverage.